PharmaLundensis (PHAL) investor relations material

Executive summary

• Net sales remained at 0 SEK for the quarter, unchanged year-over-year.

• Loss after financial items was -1,560,142 SEK, compared to -1,447,108 SEK last year.

• Equity ratio as of March 31, 2026, was 33.8%.

• A rights issue in February raised approximately 2 million SEK.

• Plans to delist shares from Spotlight to facilitate international financing.

Financial highlights

• Net loss per share improved to -0.02 SEK from -0.03 SEK year-over-year.

• Operating expenses totaled -1,513,485 SEK, up from -1,360,770 SEK year-over-year.

• Cash and bank balances increased to 1,969,368 SEK from 1,163,714 SEK at year-end.

• Total assets stood at 9,465,188 SEK as of March 31, 2026.

• Cash flow from operations was -1,109,610 SEK for the quarter.

Outlook and guidance

• Plans to conduct a smaller rights issue in autumn to sustain operations until a major international investor is secured.

• First clinical study with Phal-501 expected to complete in 12–18 months.

• Targeting $6 million USD from international investors for clinical studies and GMP production.